408 related articles for article (PubMed ID: 33117369)
1. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
Front Immunol; 2020; 11():573405. PubMed ID: 33117369
[TBL] [Abstract][Full Text] [Related]
2. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
[TBL] [Abstract][Full Text] [Related]
3. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
5. TIGIT immune checkpoint blockade restores CD8
Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
[TBL] [Abstract][Full Text] [Related]
6. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
7. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
8. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
9. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
Preillon J; Cuende J; Rabolli V; Garnero L; Mercier M; Wald N; Pappalardo A; Denies S; Jamart D; Michaux AC; Pirson R; Pitard V; Bagot M; Prasad S; Houthuys E; Brouwer M; Marillier R; Lambolez F; Marchante JR; Nyawouame F; Carter MJ; Baron-Bodo V; Marie-Cardine A; Cragg M; Déchanet-Merville J; Driessens G; Hoofd C
Mol Cancer Ther; 2021 Jan; 20(1):121-131. PubMed ID: 33277440
[TBL] [Abstract][Full Text] [Related]
10. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
11. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
[TBL] [Abstract][Full Text] [Related]
12. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
[TBL] [Abstract][Full Text] [Related]
13. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Zhang Q; Bi J; Zheng X; Chen Y; Wang H; Wu W; Wang Z; Wu Q; Peng H; Wei H; Sun R; Tian Z
Nat Immunol; 2018 Jul; 19(7):723-732. PubMed ID: 29915296
[TBL] [Abstract][Full Text] [Related]
15. TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism.
Shao Q; Wang L; Yuan M; Jin X; Chen Z; Wu C
Front Immunol; 2021; 12():688961. PubMed ID: 34659197
[TBL] [Abstract][Full Text] [Related]
16. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
17. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
18. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
19. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
